Schizophrenia and the Placenta: A New Perspective on Mental Health
Schizophrenia is a severe mental health disorder characterized by psychosis, making it challenging for individuals to distinguish between what is real and what is not. It affects approximately one percent of the Canadian population and is associated with significant health challenges, including a shortened lifespan.
Various factors can increase the risk of developing schizophrenia, such as prenatal environmental conditions (such as malnutrition or drug exposure), family history, childhood trauma, and growing up in an urban environment. Despite these known risk factors, there are still no reliable biomarkers that can predict early risk, highlighting the importance of early diagnosis for better treatment and outcomes.
Researchers are now exploring the placenta as a potential source of early indicators of schizophrenia risk, considering the concept of the placenta-brain axis. This axis suggests that when the placenta is negatively affected during pregnancy, it may also harm brain development in both the short and long term.
Recent studies have shown that certain genetic markers in the placenta are altered in pregnancies resulting in low birth weight babies, increasing the risk of schizophrenia and other negative behavioral outcomes in children.
THC Exposure and Schizophrenia Risk
A study published in Biology of Reproduction explored the effects of THC (the main psychoactive component of cannabis) on known placental markers linked to schizophrenia risk. Using a preclinical rodent model and human cell culture model, researchers found that THC exposure led to changes in schizophrenia-related genes in both offspring and placental cells.
Specifically, offspring exposed to THC showed reduced prepulse inhibition early in life, a test commonly used in diagnosing schizophrenia. Additionally, isolated human placental cells treated with THC exhibited similar increases in schizophrenia-related genes.
Implications for Clinical Practice
Identifying cannabis-specific placental markers linked to schizophrenia risk could have significant clinical implications. While stopping cannabis use during pregnancy is always recommended, interventions based on these markers could potentially reduce negative behavioral outcomes in children exposed to cannabis before birth.
Being able to identify schizophrenia risk at birth could be invaluable, considering that the disorder is typically diagnosed in late adolescence or early adulthood. Further research is needed to understand the impact of other cannabis components, such as cannabidiol, on neurodevelopment and placental markers.
Overall, these findings provide important functional evidence for clinicians and regulatory agencies as they navigate decisions and policies regarding the safety of cannabis use during pregnancy. Understanding the link between THC exposure, placental markers, and schizophrenia risk opens up new possibilities for early intervention and improved outcomes for individuals at risk.
Daniel Hardy, Professor, Department of Ob/Gyn and Physiology and Pharmacology, Western University
This article is republished from The Conversation under a Creative Commons license. Read the original article here.
